User Fee Program Renewal Gets Trickier After Ruling In Omnitrope Court Case

Renewal of FDA's Prescription Drug User Fee Act could be complicated by a federal court ruling that the agency must take action on Sandoz' application for a follow-on version of Pfizer's recombinant human growth hormone Genotropin